Background and Aims. There is growing evidence of the effects of immunosuppressive agents on "immune targets" in renal transplantation. Immunological monitoring could indirectly measure the suppressive effect of these drugs and guide early preventive interventions in transplant recipients. Due to the selective antiproliferative effect of mycophenolate mofetil (MMF) on lymphocytes, our goal was to determine whether MMF modulates peripheral blood lymphocyte subsets (PBLS) in kidney allograft patients.
B
OTH THE EFFECTIVENESS and the side effects of immunosuppressive agents for transplant patients need to be monitored. Current methods for monitoring immunosuppressive agents such as cyclosporine (CyA) and mycophenolate mofetil (MMF) are based on pharmacokinetic parameters, which correlate imprecisely with the administered dose and clinical events. [1] [2] [3] [4] [5] Although allograft biopsies may help to determine the efficacy of the immunosuppressive protocol, 6 -8 this type of monitoring is rather invasive. Furthermore, immunological monitoring should predict events prior to their clinical manifestation. 9, 10 During antilymphocyte antibody therapy, PBLS monitoring has helped to reduce the incidence of infection and acute rejection. [11] [12] [13] [14] Studies on anti-HLA antibody monitoring, intracellular T-cell cytokines, and differentiation and activation markers in peripheral blood lymphocytes offer encouraging results for the evaluation of risk situations, such as acute and chronic rejection. [15] [16] [17] [18] [19] MMF blocks the action of the type II isomer of inosine monophosphate dehydrogenase (IMPDH), which inhibits purine synthesis and results in a relatively selective antiproliferative effect on lymphocytes.
20, 21 The aim of this study was to investigate the changes in PBLS during MMF therapy in kidney transplant recipients.
SUBJECTS AND METHODS Subjects and Study Protocol
Sixty-five kidney allograft recipients were assessed in an observational nonrandomized study for 12 months. Patients were divided into three groups according to the immunosuppressive regimen. Patients with abnormal renal function and previously treated with P and CyA started taking MMF (Group A) to intensify the immunosuppressive regimen. In this group, we introduced MMF progressively in the next two divided doses scheme: 1 g/d during the first month of follow-up, and thereafter 2 g/d. Inclusion criteria was serum creatinine (SCr) between 1.5 and 3.1 mg/dL. Exclusion criteria were time since transplantation surgery less than 12 months, leukocyte count Ͻ3500/mm 3 , severe neoplasm, or infectious disease before or during the study and connective tissue disease as the primary renal disease. Two control recipient groups on P and CyA (group B) and P, CyA, and Aza (group C) were assessed using the same inclusion and exclusion criteria.
Among group A patients, we recorded age; sex; primary renal disease; time since surgery (years); P, CyA, Aza, and MMF doses (mg/body weight/d); CyA trough blood level (ng/mL); peripheral blood CD3
ϩ CD3 Ϫ ; CD19 ϩ ; and absolute lymphocyte counts (cells/L) and CD4/CD8 ratios at baseline, 1, 3, 6, and 12 months after adding MMF. The same variables were recorded at the same time points in the control group patients, but there was no baseline measurement because these recipients did not change their previously established immunosuppressive regimen.
METHODS
Blood samples were drawn from the patients between 8:00 and 10:00 AM. CyA trough blood levels were determined using the Emit 2000 Assay (Syva Company, Dade Behring Inc) in a Cobas Mira Chemistry Analyzer (Roche Diagnostic Systems, Inc). PBLS were determined by tri-color cell analysis using a Cytoron Absolute Flow Cytometer with an argon laser and Immuno Count II software (Ortho, Diagnostic, Fla, USA). Peripheral blood lymphocytes were exposed to a saturating concentration of monoclonal antibodies for 20 minutes at room temperature. The following monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), or cyanate-5-phycoerythrin (CyP) (Ortho Trio) were used: anti-CD3, -CD4, -CD8, -CD16, and -CD19. Absolute lymphocyte count was obtained as the sum of CD3 ϩ , CD16 ϩ CD3 Ϫ , and CD19 ϩ counts. Ortho Trio Control reagent was used as a negative control.
Statistical Analysis
Data are expressed as mean values Ϯ SD. Analyses were performed with SPSS 9.0 and Statgraphics Plus software packages using factorial analysis by sampling time and treatment group with generalized linear models for estimable equations and "ad hoc" methods. Student's t test and the chi-square test were used when necessary. Differences were considered statistically significant at P Ͻ .05.
RESULTS
There were no significant differences between groups with respect to underlying primary disease, sex, average age, and time since surgery (Table 1) . CyA doses at month 12 were lower in groups A and B, whereas in group C they remained constant (Table 2 ). No differences were found between P doses and CyA trough blood levels in the intra-and intergroup analyses. In group A, the MMF dose in the first month was lower than in the final months, which were similar (Table 3) . In group C, there were no changes over time in Aza doses (P ϭ .57). Table 4 summarizes the results of intra-and intergroup analyses of PBLS. In group A, absolute lymphocyte counts at months 6 and 12 were lower than at baseline and 1 and 3 months. This reduction was also observed in CD3 ϩ , CD3 ϩ CD4 ϩ , CD3 ϩ CD8 ϩ , and CD16 ϩ CD3 Ϫ lymphocyte counts at the same time points. CD19 ϩ lymphocyte counts were significantly lower at 3, 6, and 12 months than at baseline and 1 month. The CD4/CD8 ratio increased gradually: the ratio was lower at baseline than at 1, 3, 6, and 12 months and was lower at 1 month than at 12 months. Intergroup comparisons of these counts and ratios in groups B and C, respectively, were not significant.
Absolute lymphocyte counts were lower in group C than in groups A and B at baseline and at 3 months, but the differences were not significant. At 6 months, lymphocyte absolute counts were lower in groups A and C than in group B, but differences were not significant. There were no differences between groups at 1 and 12 months. CD3 ϩ lymphocyte counts were lower in group C than in group B at baseline, 3 months, and 6 months, but no differences were found between these groups and group A. There were no differences between groups in CD3 ϩ counts at 1 and 12 months.
Baseline CD3 ϩ CD8 ϩ lymphocyte counts were lower among group C than groups A and B, but differences were not significant. Evidence of an almost statistically significant difference (P ϭ .06) was detected at months 3 and 6, but differences could not be demonstrated in any pairwise comparisons between groups. There were no differences between groups in CD3 ϩ CD8 ϩ counts at 1 and 12 months. CD4/CD8 ratios at baseline and 1 and 3 months were higher among group C than in groups A and B, but these differences were not significant. No differences in ratios were found between groups at 6 months. At 12 months, the CD4/CD8 ratio was higher in group C than in group B, while group A had an intermediate value.
There were no between-group differences in CD3
, and CD19 ϩ lymphocyte counts.
DISCUSSION
Although numerous tests have been examined in the search for "immunological criteria" to monitor renal transplant patients, the results have been too inconclusive for their incorporation into clinical practice. 22 Nevertheless, some problems related to transplantation, such as chronic allograft nephropathy, have yet to be resolved, and others, such as viral infections, may have been increased by the use of more potent and selective immunosuppressive regimens. [23] [24] [25] Therefore, there is a clear need for solid and continuous development of immunological monitoring.
In the present study in renal transplant recipients, we attempted to evaluate modulation of PBLS by MMF. Our results indicate significant changes in these cells among the MMF-treated group, which do appear to be related to posttransplant immunosuppressant. There was a progressive reduction in all subsets starting with the CD19 ϩ lymphocyte count from the third month after adding MMF and in all other PBLS after the sixth month. In contrast to acute severe peripheral blood lymphocyte depletion that recurs during antilymphocyte antibody therapy, MMF caused a progressive reduction in PBLS and a later additional reduction, which suggests that it may have a cumulative effect. This delayed reduction may be reason why the study by Mathieu and colleagues, 26 which assessed the effect of MMF on peripheral blood CD2 ϩ , CD4 ϩ , and CD8 ϩ lymphocytes in cardiac transplant recipients at three time points during the first month postsurgery, did not find significant differences in these lymphocyte subsets. Based on the results of each intercontrol group analysis, where all subsets showed similar changes, we can state that MMF was the only reason for the changes in PBLS in the MMFtreated group and that they were not caused by the "natural immunological evolution" of the transplantation. We were not able to determine whether the MMF doses used have reached the "ceiling dose for lymphocyte reduction." With respect to intergroup analysis, we expected that all lymphocyte counts would be higher in group B than in group C due to the antimetabolitic effect of Aza on lymphocytes, whereas in group A these subsets might be reduced from similar levels observed in group B at the beginning of the study to levels closer to group C at the end of the study. However, we did not obtain these results: In the five intergroup comparisons made, we only observed significant differences in CD3 ϩ , CD3 ϩ CD8 ϩ , and absolute lymphocyte counts, and we were not able to define a clear temporal trend for these changes.
Previous studies have reported different effects of MMF on PBLS. Lupus patients treated with this drug show no significant changes in CD3 ϩ , CD3 ϩ CD4 ϩ , CD3 ϩ CD8 ϩ , and absolute lymphocyte counts at 6 months after adding MMF: only the mean natural killer (NK) lymphocyte count was significantly reduced. 27 In this study, mean absolute lymphocyte counts and PBLS were lower than in our study. This difference could be due to previous therapy (cyclophosphamide, antimalarial drugs, and/or steroid) or to lupus disease itself in this type of patients.
Malinowski and colleagues 28 have established the effect of different antirejection regimens on percentages of PBLS in kidney transplant recipients. The Aza ϩ CyA regimen produced lower B and NK lymphocytes and higher CD3 ϩ and CD3 ϩ CD8 ϩ lymphocytes than the CyA ϩ MMF regimen, in contrast to our results. However, the change in the CD3 ϩ CD4 ϩ count was similar to that observed in our study. The difference in the results may have been due to the shorter time since surgery (a mean of 5 months in the latter study), and a long-term study might have achieved effects similar to ours.
In conclusion, our findings suggest that (1) MMF modulates all PBLS in kidney allograft patients, causing a progressive reduction that occurs earlier in the CD19 ϩ subset, and (2) these changes are not due to the "natural immunological evolution" of the transplantation. Finally, the need to reduce situations of risk to recipients and grafts, in addition to growing evidence of immunomodulation related to immunosuppressive regimens in transplant patients, offers an interesting method for individualizing drug doses, where recipient immunological status acquires greater prominence in helping us to understand and adopt better preventive interventions in our patients.
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